Navigation Links
Takeda Initiates Phase 3 Clinical Trial Program in the United States, Latin America, and Europe for Investigational Type 2 Diabetes Therapy TAK-875
Date:10/17/2011

OSAKA, Japan, Oct. 18, 2011 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") and its wholly-owned subsidiaries, Takeda Global Research & Development Center, Inc. ("TGRD U.S."), and Takeda Global Research & Development Centre (Europe), Ltd. ("TGRD Europe"), announced today the initiation of the Company's Phase 3 clinical trial program for TAK-875, an investigational therapy for type 2 diabetes. The program will be conducted across the United States (U.S.), Latin America, and Europe. TAK-875 is the first GPR40 agonist to reach late stage (Phase 3) clinical development.

Completed studies of TAK-875, discovered by Takeda, have suggested glucose-lowering effects in patients with type 2 diabetes by enhancing glucose-dependent insulin secretion.

"Takeda is committed to enhancing the clinical investigation of TAK-875 in order to accelerate the development of a potential new type 2 diabetes treatment option for patients and healthcare professionals," said Thomas Strack, M.D., vice president, clinical science, Takeda Global Research & Development Center, Inc., U.S. "An outcome of our robust focus on diabetes over many years, TAK-875 was discovered by Takeda based on our GPCR research and is the first GPR40 agonist to reach late stage (Phase 3) clinical development. TAK-875 is being developed globally, with Phase 3 trials already underway in Japan."

The first Phase 3 trial in the U.S./Europe program, a double-blind, randomized, 24-week safety and efficacy study, will enroll approximately 450 patients with type 2 diabetes who are not adequately controlled on diet and exercise, at approximately 140 sites in the U.S., Latin America, and Europe. The study's primary endpoint will be the change in HbA1c at week 24 while other endpoints will include the assessment of a clinically meaningful response based on reaching HbA1c targets, changes in fasting plasma glucose (FPG) and two-hour postprandial plasma glucose (PPG). Results are ex
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Takeda Completes Acquisition and Names New CEO of Nycomed
2. Amylin and Takeda Discontinue Development of Pramlintide/Metreleptin Combination Treatment for Obesity Following Commercial Reassessment of the Program
3. Takeda Resubmits New Drug Applications in the U.S. for Investigational Type 2 Diabetes Therapies Alogliptin and the Fixed-Dose Combination Alogliptin/Pioglitazone
4. Takeda Responds to U.S. Food and Drug Administration Update to Safety Review of ACTOS (pioglitazone HCl)
5. Takeda to Acquire Nycomed
6. Amylin and Takeda Voluntarily Suspend Clinical Activities in Obesity Trial
7. Intra-Cellular Therapies and Takeda Enter into Worldwide Collaboration to Develop and Commercialize Compounds for Schizophrenia
8. Handa Pharmaceuticals Announces Submission of Its First-to-File ANDA for Takedas DEXILANT®
9. Takeda Submits New Drug Application in the U.S. for Azilsartan Medoxomil Plus Chlorthalidone, an Investigational Fixed-Dose Combination for the Treatment of Hypertension
10. Takeda Enters Into Global Strategic Partnerships With Covance and Quintiles
11. Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... BioPharma, Inc. (PDL) (NASDAQ: PDLI ) today reported ... Total revenues for the first quarter ... $136.8 million in the first quarter of 2014. Revenues ... million in royalty and license payments from PDL,s licensees ... net royalty payments from acquired royalty rights and a ...
(Date:5/6/2015)... Inc. (NYSE: LCI ) today reported financial results ... 2015.  For the fiscal 2015 third ... $80.0 million in last year,s third quarter.  Gross profit ... sales, from $56.1 million, or 70% of net sales.  ... from $10.6 million for the fiscal 2014 third quarter.  ...
(Date:5/6/2015)... May 6, 2015 The Parenteral Drug Association ... finalized agreement with Richard M. Johnson to ... "We are very pleased to have Richard Johnson ... Hal Baseman , the Chair of the Board of ... and growth.  Richard has led a strong staff and ...
Breaking Medicine Technology:PDL BioPharma Announces First Quarter 2015 Financial Results 2PDL BioPharma Announces First Quarter 2015 Financial Results 3PDL BioPharma Announces First Quarter 2015 Financial Results 4PDL BioPharma Announces First Quarter 2015 Financial Results 5PDL BioPharma Announces First Quarter 2015 Financial Results 6PDL BioPharma Announces First Quarter 2015 Financial Results 7Lannett Reports Strong Fiscal 2015 Third-quarter Financial Results 2Lannett Reports Strong Fiscal 2015 Third-quarter Financial Results 3Lannett Reports Strong Fiscal 2015 Third-quarter Financial Results 4Lannett Reports Strong Fiscal 2015 Third-quarter Financial Results 5Lannett Reports Strong Fiscal 2015 Third-quarter Financial Results 6Lannett Reports Strong Fiscal 2015 Third-quarter Financial Results 7Lannett Reports Strong Fiscal 2015 Third-quarter Financial Results 8PDA Extends Richard M. Johnson as President/CEO for Six Additional Years 2
... Indicate Bioequivalent Pharmacokinetics With Reduced Risk,of ... April 25, 2007 /PRNewswire-FirstCall/ -- ADVENTRX,Pharmaceuticals, ... company focused on commercializing proprietary product,candidates ... infectious diseases,today announced positive results from ...
... 2007 - Basilea Pharmaceutica Ltd.,(SWX:BSLN) reported today ... severe chronic hand eczema can benefit from,re-treatment ... alitretinoin was found to be effective in ... to topical treatments.,This pivotal trial demonstrated that ...
Cached Medicine Technology:ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion) 2ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion) 3ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion) 4ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic,Testing of ANX-514 (Docetaxel Emulsion) 5Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 2Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 3Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 4Basilea Reports Positive Re-treatment Results from a Second Phase,III Trial of Alitretinoin for Patients with Severe Chronic Hand,Eczema 5
(Date:5/6/2015)... 06, 2015 A quality built chicken coop condo ... yet practical way to raise chickens on a pasture. By ... Condo, it will have a chicken tractor that stands up to ... many years, as it is able to flex to uneven ground ... of the land are fertilized, and it will help provide the ...
(Date:5/6/2015)... The Canton Group is joining Lardarius ... 6th annual charity softball game. The event takes place on ... Stadium. Past years guests include Joe Flacco, John Harbaugh, Ed ... on sale if you are interested in attending. , ... such as SOAR Baltimore and The CollegeBound ...
(Date:5/6/2015)... Animals make just as good friends as they do pets. ... An Ohio veterinarian has been observing this for ... advantages of owning a pet. , “When animals and humans ... there are proven health benefits for people-- including physical, mental ... Animal Medical Center of Streetsboro said. Every May, ...
(Date:5/6/2015)... Anitha Nallari, MD has joined ... Inc. in Columbus, OH. Dr. Nallari will see patients ... in breast cancer, lung cancer, GI and gallbladder cancer, head ... benign hematology. , Dr. Anitha Nallari is Board ... American Board of Internal Medicine. She completed her medical education ...
(Date:5/6/2015)... Anitoa Systems, (“Anitoa”), a Palo Alto startup established ... has successfully demonstrated a handheld real time quantitative-polymerase-chain-reaction system ... handheld qPCR is shown to be capable of detecting ... B, C, and E. Coli. This qPCR system has ... over 9 orders of magnitude dynamic range. A ...
Breaking Medicine News(10 mins):Health News:Chicken Coop Condo Launches the Chicken Tractor 2Health News:The Canton Group Sponsors Ravens Charity Softball Event 2Health News:The Canton Group Sponsors Ravens Charity Softball Event 3Health News:Veterinarian Supports 2015 HABRI Study Citing Increase in Health Advantages of Pet Owners 2Health News:Veterinarian Supports 2015 HABRI Study Citing Increase in Health Advantages of Pet Owners 3Health News:New Oncologist to Join Hematology Oncology Consultants, Inc. 2Health News:New Oncologist to Join Hematology Oncology Consultants, Inc. 3Health News:Anitoa Systems Demonstrates Compact qPCR using Ultra Low-Light CMOS Bio-Optical Sensor 2Health News:Anitoa Systems Demonstrates Compact qPCR using Ultra Low-Light CMOS Bio-Optical Sensor 3
... test, researcher says, , THURSDAY, Dec. 3 (HealthDay News) -- ... between vitamin D and heart disease. , People with high ... D activation in the body were found to be twice ... heart failure, the study found. , The finding may lead ...
... LONDON, Dec. 3 Chiltern International Limited (Chiltern), a global ... in Europe, the Americas and Asia, today announces the appointment ... Global Quality & Medical Affairs. Dr. Moore is based at ... physician with 15 years of industry experience. Prior to joining ...
... , PASADENA, Calif., Dec. 3 For California,s 3.4 ... one of the most significant threats to not only their ... , "As the recession and market declines have taken their ... shore up their financial safety net with enhanced disability coverage," ...
... , Research could lead ... prevent mutations known to result in cancer and genetic diseases ... for the first time observed the movement of a single ... one. More significantly, they have identified a previously unknown step ...
... ... test – HiFi DNA Tech sues FDA on December 11 for blocking new technology. ... Trumbull, CN (PRWEB) December 2, ... invasive cancer workup procedure, also known as colposcopic biopsy, is harmful and may be ...
... , , NEW YORK, ... human H1N1/09 Type A influenza ("Swine Flu") has reached a ... with at least 6,500 fatalities. Since there is no ... numbers undoubtedly understate the real situation. , ...
Cached Medicine News:Health News:Vitamin D May Be Tied to Heart Disease Via Genes 2Health News:Chiltern Names Dr. Sharon Moore as Executive VP, Global Quality & Medical Affairs 2Health News:New Disability Income Insurance Options Provide More Choice for California's Small Business Owners 2Health News:New Disability Income Insurance Options Provide More Choice for California's Small Business Owners 3Health News:New Disability Income Insurance Options Provide More Choice for California's Small Business Owners 4Health News:Wayne State Researchers Report a Possible 'Proofreading' Step in DNA Synthesis by Observing Single Molecules of DNA Polymerase 2Health News:Wayne State Researchers Report a Possible 'Proofreading' Step in DNA Synthesis by Observing Single Molecules of DNA Polymerase 3Health News:Harmful Procedures on Young Women Caused by Outdated HPV test, not by Pap Test 2Health News:Buchang Global Health Forum 2009: An Innovative Approach for Management of H1N1 Swine Flu 2
... Vacuum Manifold system for sample processing consists ... a vacuum is applied, a chemical-resistant polypropylene ... convenience in sample handling. The manifold is ... up to 12 samples simultaneously. Loading, washing, ...
For regulating sample flow rate when using the QIAvac 24 Plus;...
For processing mini spin columns on QIAvac 6S;...
For monitoring vacuum pressure, suitable for use with all QIAvac manifolds;...
Medicine Products: